Heron Therapeutics, Inc. (HRTX)

2,5500 -0,1000 (-3,77%) Al cierre: 04:00PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 126

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Craig Alexander Collard	CEO & Director	N/A	N/A	1966
Ms. Ira Duarte	Executive VP & CFO	N/A	N/A	1970
Mr. Ryan Craig	Vice President of Marketing	N/A	N/A	N/A
Mr. Sean T. Ristine	Senior Vice President of Human Resources	N/A	N/A	1970
Mr. Robert Sullivan	Senior VP of Oncology Care Franchise & Commercial Operations	N/A	N/A	1978
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer	N/A	N/A	1962
Jeff Cohn	Executive Director, Assistant General Counsel & Assistant Secretary	N/A	N/A	N/A

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Heron Therapeutics, Inc., a día 1 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 7; Tablero: 4; Derechos de los accionistas: 1; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.